GlassScriptPhysician profile
Pareena Bilkoo
NPI 1285749705
$5,047.17
in general payments reported to CMS, 2019-2025
41 companies · $1,292 in 2025
The $1,292 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $190 · 2021: $180 · 2022: $931 · 2023: $963 · 2024: $1,020 · 2025: $1,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,088 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,087.89 |
| Education | $187.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $569.49 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $460.74 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $428.94 | 2020-2025 | Uptravi, Opsumit, Opsynvi |
| Janssen Pharmaceuticals, INC | $404.40 | 2019-2024 | Xarelto |
| Philips North America LLC | $390.98 | 2022-2025 | (Ck4) Mcot, Ecc Solutions |
| Astrazeneca Pharmaceuticals LP | $341.60 | 2019-2025 | Saphnelo, Farxiga, Breztri |
| Amgen INC. | $226.06 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $200.97 | 2019-2024 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $193.12 | 2019-2024 | Lifevest |
| Boston Scientific Corporation | $192.05 | 2019-2025 | Cds - Mct/Cem Monitoring, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.86 | 2022-2024 | Jardiance |
| Glaxosmithkline, LLC. | $141.56 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Ucb, INC. | $131.60 | 2025 | Bimzelx |
| Novo Nordisk INC | $115.28 | 2023-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $95.24 | 2024-2025 | Zepbound, Mounjaro, Taltz |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pareena Bilkoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.